Neuralstem (CUR) Tops Q3 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. NDAQ
9. TSCO
10. BE

Go back to Neuralstem (CUR) Tops Q3 EPS by 1c

Neuralstem Reports Third Quarter 2015 Financial Results

November 9, 2015 9:04 AM EST

GERMANTOWN, Md., Nov. 9, 2015 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR) a biopharmaceutical company leveraging its unique human neural stem cell-derived platform to identify and develop novel neurogenic therapies for diseases of the central nervous system (CNS), today reported its financial results and business update for the three and nine months ended September 30, 2015.

Neurogenic Oral, Small Molecule Program with NSI-189 Advancing to Phase 2.

NSI-189 Major Depressive Disorder (MDD) Program: Neuralstem filed its Phase II clinical trial protocol for the treatment of MDD with the FDA in September, 2015.... More